



RAC-US^{Q&As}

Regulatory Affairs Certification (RAC) US

Pass RAPS RAC-US Exam with 100% Guarantee

Free Download Real Questions & Answers **PDF** and **VCE** file from:

<https://www.geekcert.com/rac-us.html>

100% Passing Guarantee
100% Money Back Assurance

Following Questions and Answers are all new published by RAPS
Official Exam Center

-  **Instant Download** After Purchase
-  **100% Money Back** Guarantee
-  **365 Days** Free Update
-  **800,000+** Satisfied Customers





QUESTION 1

Which of the following BEST describes the content of the "Physical, Chemical, and Pharmaceutical Properties and Formulation" section of an IB?

- A. A review of available data to support the determination of the chemical structure and physical attributes of the drug substance plus batch analysis and stability data for the finished formulation
- B. A detailed summary of the physical and chemical properties of the drug product with a signed expert statement addressing the suitability and stability of the formulation for its intended use
- C. A description and flow chart illustrating the synthetic route for the active ingredient and the preparation method of the finished product
- D. A brief summary of relevant physical, chemical, and pharmaceutical properties: instructions for storage and handling of the dosage form: and a description of the formulation

Correct Answer: D

QUESTION 2

A global company is developing a sophisticated implantable medical device that is coated with antibiotics and biologics to enhance its efficacy. The product is marketed in Country X, where it is regulated as a medical device. The same product, without the antibiotics and biologics, is marketed as a medical device in Country Y. The company is proposing to start marketing the coated device in Country Y. Which regulatory approach should the company propose?

- A. Submit the product for review as a pharmaceutical product in Country Y.
- B. Submit the product as a medical device in Country Y as the product is already marketed in Country X as a medical device.
- C. Apply for review of the additional part of the product as a pharmaceutical product in Country
- D. Examine decisions made about similar products in Country Y to propose the classification of the product.

Correct Answer: CD

QUESTION 3

A protocol for a pivotal registration trial of a new product is submitted to a major regulatory authority for review and approval. The regulatory authority issues the company a written commitment that if the studies are completed as outlined in the protocol and the results meet the pre-specified criteria for efficacy and safety, the product will be approved.

During the final week of the review of the marketing application, which has fully met all pre-specified criteria, the company receives a letter from the regulatory authority stating that it no longer believes that the product will be approved based on a recent withdrawal of a similar product in another country.



What is the BEST response?

- A. Notify the regulatory authority regarding its obligation to honor the commitment to approve the application.
- B. Consult with the legal department to discuss the best course of action.
- C. Review the regulatory guidelines to determine how to proceed.
- D. Request a meeting with the regulatory authority to discuss the application.

Correct Answer: D

QUESTION 4

A company is developing a new medical device. During which initial stage is it MOST appropriate for a regulatory affairs professional to become involved?

- A. Concept development and validation
- B. Concept development and early technical design
- C. Early technical design and product release
- D. Product release and validation

Correct Answer: B

QUESTION 5

In a distribution contract for high-risk medical devices, which of the following regulatory requirements is the MOST important for the distributor?

- A. Local reimbursement requirements
- B. Service operation procedures
- C. Training program for sales people
- D. Written procedure for product traceability

Correct Answer: C
